Prophase Labs, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
ProPhase Labs reports a net loss of $14.7 million for 2025, following the Chapter 11 bankruptcy filing of its diagnostic subsidiaries and a strategic shift toward genomics and biotechnology.
OTC.Pink
10-K/A: ProPhase Labs Files Amendment to 10-K to Include Omitted Information and Subsequent Event Disclosure
ProPhase Labs files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, principal accountant fees, and a subsequent event relating to executive salary deferrals.
OTC.Pink
ProPhase Labs reports a significant revenue decrease in 2024 due to reduced diagnostic services, while focusing on genomics and biopharmaceutical growth.
OTC.Pink
ProPhase Labs has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.
OTC.Pink
ProPhase Labs has amended and restated its bylaws, outlining procedures for stockholder meetings, director nominations, and other corporate governance matters.